The entire PCA process, including tissue collection, ordering multi-omic molecular tests, computational and data analytics, and reporting of therapy options, is managed by Perthera, thus creating a conduit connecting patients with molecular profiling testing, and ultimately to clinical trials.
"Perthera differentiates itself from other enterprises involved in precision medicine because its 'multi-omic' approach goes beyond genomic testing to include proteomic analysis and other tests that develop a full molecular understanding of each patient's cancer," continued Mignatti.
This unique ecosystem allows Perthera to identify and list relevant clinical trials that may be appropriate for the patient based on their molecular profile rather than requiring the patient or oncologist to discover them by themselves.
ABOUT PERTHERA, INC.: Perthera is a founder- and growth fund-backed precision medicine company based in McLean, VA. Since its founding five years ago, it has achieved over 1,000 case histories, often working in alliance with cancer advocacy agencies, hospitals, community oncology practices, and academia. For every patient, Perthera, Inc. seeks to become the precision medicine partner on their cancer care team, providing the widest, deepest, and most independent range of service possible.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/perthera-inc-enters-a-collaboration-with-major-pharmaceutical-company-to-identify-cancer-patients-for-clinical-trials-300399979.html
SOURCE Perthera, Inc.